Physician profile
Amanda Mileham
NPI 1356011423
$819.85
in general payments reported to CMS, 2019-2025
15 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $180 · 2024: $471 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $336.14 | 2024-2025 | |
| Corium, LLC | $61.35 | 2023-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $58.21 | 2023-2024 | Jornay Pm |
| Ars Pharmaceuticals Operations, INC. | $54.00 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $48.64 | 2023-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Kaleo, INC. | $46.63 | 2023-2024 | Auvi-Q |
| Alk-Abello, INC | $41.26 | 2025 | Neffy |
| Pfizer INC. | $26.91 | 2024 | |
| Collegium Pharmaceutical, INC. | $24.77 | 2025 | Jornay Pm |
| Tris Pharma INC | $24.46 | 2025 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $23.88 | 2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $23.05 | 2024 | |
| Seqirus USA INC | $20.93 | 2023 | Flucelvax Quadrivalent |
| Verrica Pharmaceuticals INC. | $16.13 | 2023 | Ycanth |
| Neos Therapeutics, LP | $13.49 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mileham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.